Evaluating the protective efficacy of a trivalent vaccine containing Akabane virus, Aino virus and Chuzan virus against Schmallenberg virus infection by unknown
VETERINARY RESEARCH
Hechinger et al. Veterinary Research 2013, 44:114
http://www.veterinaryresearch.org/content/44/1/114RESEARCH Open AccessEvaluating the protective efficacy of a trivalent
vaccine containing Akabane virus, Aino virus and
Chuzan virus against Schmallenberg virus infection
Silke Hechinger, Kerstin Wernike and Martin Beer*Abstract
Schmallenberg virus (SBV), an arthropod borne pathogen, spread rapidly throughout the majority of Europe since
2011. It can cause a febrile disease, milk drop, diarrhea, and fetal malformation in ruminants. SBV, a member of the
Simbu serogroup within the genus Orthobunyavirus, is closely related to Akabane virus (AKAV) and Aino virus
(AINOV) among others. In the present study, 4 Holstein-Friesian calves were immunized twice four weeks apart with
a multivalent, inactivated vaccine against AKAV and AINOV. Another 4 calves were kept as unvaccinated controls. All
animals were clinically, serologically and virologically examined before and after challenge infection with SBV.
AKAV- and AINOV-specific neutralizing antibodies were detected one week before challenge infection, while
SBV-specific antibodies were detectable only thereafter. SBV genome was detected in all vaccinated animals and 3
out of 4 controls in serum samples taken after challenge infection. In conclusion, the investigated vaccine was not
able to prevent an SBV-infection. Thus, vaccines for other related Simbu serogroup viruses can not substitute
SBV-specific vaccines as an instrument for disease control.Introduction
Schmallenberg virus (SBV), a member of the Simbu
serogroup within the genus Orthobunyavirus, family
Bunyaviridae, emerged in Europe in autumn 2011 [1].
Thereafter it spread rapidly throughout large parts of the
continent [2]. Blood sucking insects, particularly midges
of the Culicoides obsoletus complex, are involved in the
transmission of the pathogen [3-5]. In adult cattle, sheep
and goats mild febrile disease accompanied by reduction
of milk yield may be observed, sometimes associated with
diarrhea [6]; inapparent infection may occur as well. Fetal
infection during a critical phase of pregnancy may lead to
damage of the central nervous system and the musculo-
skeletal structures [7,8]. Stillbirth or birth of weak calves,
lambs or kids, abortion and dystocia are the possible
consequences [6,9]. Experimental infection of cattle re-
sulted in RNAemia for a few days and infection of diverse
tissues throughout the body of the host [1,10].
SBV is closely related to Sathuperi virus (SATV) and
Douglas virus (DOUV) [11,12], and it was demonstrated* Correspondence: martin.beer@fli.bund.de
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reproduction in any medium, provided the orthat SBV-specific antibodies are able to neutralize infectiv-
ity of DOUV, SATV and Aino virus (AINOV) in vitro [11].
Additionally, serological cross-reactions between Akabane
virus (AKAV), AINOV, DOUV, SATV and Shamonda
virus (SHAV) were described previously [13]. These cross-
reactions were detected in complement fixation tests
(CFT), not in neutralization tests. Consequently, the con-
tribution of such antibodies to a protective effect might be
limited. Beyond that, AINOV and AKAV cause symptoms
in ruminants which are similar to those of an SBV-
infection [14,15], and vaccines have been developed for
disease control [16,17]. Chuzan virus (CHUV, family
Reoviridae, genus Orbivirus) is another teratogenic patho-
gen of ruminants which occurs in Asia [18,19]; it has been
included into a multivalent vaccine together with AKAV
and AINOV. In the present study, the possible cross-
protection of this multivalent vaccine against a subsequent
challenge infection with SBV was investigated.Materials and methods
Experimental design
The experimental protocol was reviewed by a state ethics
commission and has been approved by the competenttral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Fisheries of Mecklenburg-Vorpommern, Rostock, Germany,
ref. LALLF M-V TSD/7221.3-1.1-004/12).
Eight SBV-naive female Holstein-Friesian calves were
divided in 2 groups of 4 individuals. The average age was
9.4 months at the first vaccination. The animals were
housed under BSL 3 conditions during the entire study to
prevent a natural SBV-infection.
Animals of group 1 (C01-C04) were immunized
intramuscularly twice 4 weeks apart with 3 mL of a
trivalent inactivated vaccine for AKAV, AINOV and
CHUV (Nisseiken Bovine Abnormal Parturition Trivalent
Inactivated Vaccine, Nisseiken Co., Ltd, Japan). The effi-
cacy and safety of this vaccine have been investigated
previously [16]. The second group (C05-C08) was used as
unvaccinated control. Injection sites were monitored daily
for 4 days after both vaccinations.
Six weeks after the first vaccination all animals were
inoculated subcutaneously with 2 × 0.5 mL of an SBV
field strain that was only passaged in cattle [10]. After
the challenge infection the animals were monitored for
clinical signs by veterinarians for eight days.
Rectal body temperature was recorded daily. Blood
samples were collected weekly, starting from day 7
after the first vaccination (7 days post vaccination
(dpv)), as well as daily on the 8 days following
challenge. Serum samples were analyzed with a com-
mercially available SBV antibody ELISA (ID Screen®
Schmallenberg virus Indirect, IDvet, France) and in
standard microneutralization tests (SNT) against SBV,
AKAV and AINOV [20].
Samples of spleen, tonsils, and mesenteric and man-
dibular lymph nodes were taken at autopsy and homoge-
nized in 1 mL of Minimum Essential Medium (MEM).RNA extraction and real-time RT-PCR
RNA was extracted from serum and tissue samples using
the MagAttract Virus Mini M48 Kit (Qiagen, Germany)
according to the manufacturer’s recommendations.
SBV genome load was determined by an SBV-specific
reverse transcription real-time PCR (real-time RT-PCR)
as described previously [21] with an external standard
based on the small (S) genome segment.Results
Clinical observation and pathology
None of the animals showed any signs of clinical disease.
Body temperatures were within a normal range for all ani-
mals. The measured temperatures never exceeded 39.5 °C.
Additionally, no adverse side effects were observed follow-
ing either vaccination. Autopsy did not reveal any signifi-
cant gross lesions.Serology
All animals were seronegative for SBV, AINOV and
AKAV before first vaccination (Figure 1).
In one vaccinated animal first AKAV-specific antibodies
could be detected one week after the first vaccination and
two weeks prior to challenge, respectively. All immunized
animals were SNT-positive for AKAV and AINOV one
week before challenge infection. First SBV-specific neu-
tralizing antibodies were detected in two of four animals
one week after challenge (Figure 1). Two weeks after chal-
lenge infection all four vaccinated animals were positive
for SBV, both in SNT and ELISA.
The four control animals remained seronegative for
AKAV- and AINOV throughout the study. SBV-specific
antibodies were detected starting from the second week
after challenge infection, with three animals being posi-
tive in the SNT, and one animal scoring positive in the
ELISA. A second control animal showed a positive reac-
tion in the ELISA in the third week after challenge infec-
tion. One control animal (C05) remained negative for
SBV in both serological assays until the end of the study.
Real-time RT-PCR
All vaccinated animals as well as three of four control ani-
mals were positive in the RT-PCR (Figure 2). SBV genome
was detected in the serum samples of all vaccinated ani-
mals and in all control animals with the exception of C05.
In group 1 (vaccinated animals) RNAemia was seen from
2 days post challenge (dpc) infection to 5 dpc in two ani-
mals (C03, C04), from 3 dpc to 6 dpc in one animal (C02)
and from 3 dpc to 7 dpc in the remaining animal (C01). In
group 2 (controls), the animals showed RNAemia from 2
dpc to 5 dpc (C06, C08) and from 1 dpc to 6 dpc (C07),
respectively.
Furthermore, SBV genome was detected in all vaccinated
animals in the mesenteric lymph nodes (average: 3.89 × 105
genome copies/mg sample material), the spleen samples
(average: 1.01 × 105 copies/mg) and mandibular lymph
nodes (average: 3.59 × 104 copies/mg). In tonsils of C01
and C03 1.55 × 105 copies/mg and 1.82 × 102 copies/mg
were detected.
In control animals C06, C07 and C08, SBV genome was
detected in mesenteric lymph nodes (average: 1.66 × 106
copies/mg) and spleens (average: 3.05 × 105 copies/mg). In
C07 and C08 mandibular lymph nodes were positive as well
(1.36 × 106 copies/mg and 5.08 × 105 copies/mg re-
spectively) and tonsils of C07 contained 4.92 × 102
copies/mg. In samples from calf C05 SBV-genome was
not detectable.
Discussion
Antibodies specific for Simbu serogroup viruses frequently
cross-react with more than one other member of this sero-
group [11,13]. Such interaction might also influence viral
Figure 1 Serology. The animals were vaccinated 6 and 2 weeks
before challenge. Bars represent one animal each. Serum samples
were tested by a commercially available SBV antibody ELISA (A) and
in standard microneutralization tests against SBV (B), AINO (C) and
AKAV (D). Horizontal dashed lines indicate the cut-off value of the
respective test. The neutralization titers are expressed as reciprocal
of the serum dilution showing 50% virus neutralization.
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vaccines against related Simbu viruses, such as AKAV and
AINOV, could potentially offer a tool for disease control
until an SBV-specific vaccine is ready for use.
Considering the current epidemiological situation vac-
cination of young female sheep or cattle before their first
pregnancy will be an important measure to eliminate the
risk of SBV-infection of naïve animals during the vulner-
able phase of fetal development. Therefore, calves instead
of cows were used in the present study. Data about the
effect of vaccination of calves were not published for the
vaccine we used but the efficacy of another inactivated
AKAV-specific vaccine in calves aged 5 to 10 months has
been proven [17]. Additionally, inactivated SBV vaccines
are efficacious in calves [22].
The trivalent AKAV/AINOV/CHUV-vaccine applied in
the present study has proven its effectiveness [16]. Neu-
tralizing antibodies against AINOV and AKAV could be
detected shortly after the second vaccination. For AKAV it
has been demonstrated, that a neutralizing titer of 16 in
experimental animals prevented RNAemia after infection
in comparison to one control animal [16]. Thus, we as-
sume that a mean neutralizing titer of 85 (minimum 40),
as detected in the present study, would have provided pro-
tection against AKAV infection. For AINOV protective
antibody titers could not be determined from the litera-
ture. However, the titers detected in the present study areFigure 2 Real-time RT-PCR results for serum samples after
challenge infection. All vaccinated animals (depicted in red) and
three out of four control cattle (black) scored positive in the
RT-qPCR for several days.
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earlier studies on this vaccine [16]. Therefore, protection
could probably have been expected in case of an AINOV-
infection also.
SBV-specific antibodies were detectable only after chal-
lenge infection. In the ELISA some low activity was seen
for the samples of vaccinated animals in week −1 and 0
(Figure 1). At the same time anti-AKAV and anti-AINOV
antibodies started to be detectable in vaccinated animals
by neutralization test. Serological cross-reaction between
close relatives of SBV (SATV, DOUV, SHAV) and AKAV/
AINOV have already been described in CFT [13]. This
test also detects non-neutralizing antibodies like anti-
nucleoprotein antibodies. As the ELISA that was used for
our analysis is based on recombinant SBV nucleoprotein
for antibody detection this can explain the results.
Unlike Goller et al. [11] we did not detect cross-
neutralization between AINOV and SBV. One possible
reason for this discrepancy is the determination of the neu-
tralizing activity of anti-AINOV/AKAV antibodies towards
SBV in the present study, but of neutralizing activity of
anti-SBV antibodies towards AINOV and other Simbu vi-
ruses by Goller et al. [11]. In contrast to the nucleoprotein-
based ELISA, neutralization depends on antibodies binding
to viral glycoproteins. This can explain that there was some
evidence of cross reactivity in the ELISA but not in the
neutralization test. Furthermore, the AINOV/AKAV anti-
bodies in our study were induced by vaccination while the
SBV-antiserum used by Goller et al. [11] was collected
following SBV-infection.
After inoculation with SBV, viral RNA was present in
serum samples of all vaccinated animals for several days
and in 7 of 8 animals SBV-RNA was detected in the lymph-
atic tissues sampled at autopsy. The same was observed in
unvaccinated control animals during SBV vaccine studies,
whereas vaccination with inactivated prototype SBV vac-
cines has been associated with reduced RNA load in serum
and tissue samples or no detection of SBV genome at all,
even if SBV-specific antibody titers were low [22].
Remarkably, highest SBV-genome loads for tissue sam-
ples were found in mesenteric lymph nodes in most ani-
mals. This is in agreement with results from earlier studies
[10]. However, the role of lymphatic tissues in the patho-
genesis of SBV infection has not been thoroughly investi-
gated so far and is a topic to which attention should be
paid in future research.
It is unknown why one animal (C05) failed to show signs
of infection both in serological tests and PCR but similar
observations have been made after experimental SBV-
infection of sheep [23]. One explanation could be a failed
injection, another one a general resistance to SBV-infection
of unknown cause.
In conclusion, protection against SBV-infection could
not be proven for the multivalent vaccine tested. Thus,vaccines for other related Simbu serogroup viruses can
not substitute SBV-specific vaccines as an instrument
for disease control.
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